03:39:21 EDT Mon 24 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

C:RVV - Revive Therapeutics Ltd. - http://www.revivethera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVV - C  79.30.015·0.021631.00.015-0.005-25.02,180.831550.015  0.02  0.0150.06  0.015Jun 21Jun 1215 min RT 2¢
CSE - C79.30.015·0.021631.00.015-0.005-25.01,634.023350.015  0.015  0.0150.06  0.015Jun 2115 min
NEO ATS - U 0.015-0.005-25.0214.0360.015  0.015  0.015Jun 2115 min
Omega - O 0.0285.0150.015  0.02  0.015Jun 2115 min
CX2 - H 0.015-0.005-25.0247.0460.015  0.02  0.015Jun 2115 min
TriAct - M 0.020.83    Sep 08-2015 min

Recent Trades - Last 10 of 55
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:11:59C0.015-0.00521,00085 Scotia1 AnonymousK
15:10:59C0.015-0.00520,00080 National Bank7 TD SecK
15:10:59C0.015-0.00510,00079 CIBC7 TD SecK
15:10:59C0.015-0.00575,0009 BMO Nesbitt7 TD SecK
15:10:59C0.015-0.00540,00080 National Bank7 TD SecK
15:10:59C0.015-0.00520,00085 Scotia7 TD SecK
15:10:59C0.015-0.00534,00085 Scotia7 TD SecK
15:10:59C0.015-0.005100,0007 TD Sec7 TD SecK
15:10:59C0.015-0.00547,0007 TD Sec7 TD SecK
15:10:59C0.015-0.00519,0007 TD Sec7 TD SecK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-06-12 12:14C:RVV0.02News ReleaseRevive receives FDA feedback on Bucillamine study
2024-06-10 11:22C:RVV0.02News ReleaseRevive receives FDA feedback for diagnostic device
2024-05-31 01:25C:RVV0.025SEDAR Interim MD & ASEDAR Interim MD & A
2024-05-31 01:18C:RVV0.025SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-04-23 10:17C:RVV0.025News ReleaseRevive receives Bucillamine FDA Type C meeting approval
2024-04-18 10:56C:RVV0.025News ReleaseRevive gets FDA acceptance for meeting request
2024-04-02 11:21C:RVV0.03News ReleaseRevive clinical study enrolls nearly 50% of sample
2024-03-27 13:25C:RVVNews ReleaseRevive submits meeting request to U.S. FDA
2024-03-19 10:11C:RVV0.03News ReleaseRevive receives notice to submit Type C meeting request
2024-03-12 09:42C:RVV0.035News ReleaseRevive recaps work on bucillamine, long COVID product
2024-02-28 18:51C:RVV0.025SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-28 18:51C:RVV0.025SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-26 16:24C:RVV0.025News ReleaseRevive Therapeutics closes $1.18M final tranche
2024-02-01 11:25C:RVV0.03News ReleaseRevive proposes phase 2/3 bucillamine clinical study
2024-01-31 17:24C:RVV0.025News ReleaseRevive closes $913,500 first tranche of placement
2024-01-24 18:00C:RVV0.04News ReleaseRevive arranges $3-million private placement
2024-01-16 11:28C:RVV0.035News ReleaseRevive talks Bucillamine for nerve agent exposure
2024-01-10 10:07C:RVV0.035News ReleaseRevive develops new bucillamine formulation
2023-12-20 13:11C:RVV0.03News ReleaseRevive shareholders approve all matters at AGSM
2023-12-18 10:14C:RVV0.03News ReleaseRevive, Attwill to develop Bucillamine formulation